본문 바로가기
  • Home

A comprehensive review on Tukhm-e-Karafs (Apium graveolens L.) with special reference to Unani System of Medicine

  • CELLMED
  • Abbr : CellMed
  • 2020, 10(3), pp.20-20
  • DOI : 10.5667/CellMed.2020.0020
  • Publisher : Cellmed Orthocellular Medicine and Pharmaceutical Association
  • Research Area : Medicine and Pharmacy > General Medicine
  • Received : May 15, 2020
  • Accepted : June 4, 2020
  • Published : August 31, 2020

Mohd Naushad 1 Mohammad Zakir 2 Najmus Sahar 3 Munawwar Husain Kazmi 4

1Sanskriti Unani Medical College & Hospital
2National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD)
3Department of Ilmul Advia, National Research Institute of Unani Medicine for Skin Disorders
4National Research Institute of Unani Medicine for Skin Disorders

Candidate

ABSTRACT

The Karafs is a dried herb of whole plant of Apium graveolens L. from Apiaceae (carrot family). The seeds (fruits) of Apium graveolens are known as Tukhm-e- Karafs in Unani Medicine. Karafs is known as Celeri in French, Apio in Spanish, Selderiji in Dutch, Syelderey in Russian and Chin in Chinese. It is cultivated in different parts of the world for its seeds as spice and green leaves and root as salad crop. Its seeds are also used for medicinal purposes in complementary and alternative medicines. In Unani it is used as a single drug or as an ingredient in compound formulations used for management in various ailments. The seeds have various pharmacological actions like hepatoprotective, diuretic and lithotriptic etc. It is commonly found in Western Asia, Europe, North Africa and various parts of India like Punjab, Uttar Pradesh and Himachal Pradesh etc. In Unani its actions are described as Mudirr-i-Bawl (Diuretic), Mufattit-i-Hasāh (Lithotriptic), Dafi‘-i-Tashannuj (Antispasmodic) and Kāsir-i-Riyāh (Carminative). It is used for the treatment of Hasah al-Kulya (Nephrolithiasis), Nafkh al-Mi‘da (Flatulence), Istisqā’ (Oedema) and Ihtibās al-Bawl (Retention of urine) etc.

Citation status

* References for papers published after 2023 are currently being built.